193 related articles for article (PubMed ID: 30821007)
21. Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098-5106.
Blood Adv; 2024 May; 8(9):2243. PubMed ID: 38743412
[No Abstract] [Full Text] [Related]
22. [Ulceration of lymphomatous skin lesions in a patient with Sezary syndrome treated with brentuximab-vedotin].
Maitrepierre F; Schissler C; Cribier B; Lipsker D
Ann Dermatol Venereol; 2020 Mar; 147(3):198-201. PubMed ID: 31959414
[TBL] [Abstract][Full Text] [Related]
23. FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?
Milunović V; Mišura Jakobac K; Kursar M; Mandac Rogulj I; Ostojić Kolonić S
Eur J Haematol; 2019 Sep; 103(3):145-151. PubMed ID: 31166030
[TBL] [Abstract][Full Text] [Related]
24. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.
Lewis DJ; Talpur R; Huen AO; Tetzlaff MT; Duvic M
JAMA Dermatol; 2017 Dec; 153(12):1302-1306. PubMed ID: 28980004
[TBL] [Abstract][Full Text] [Related]
25. Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016.
Fosså A; Smeland K; Fagerli UM; Galleberg RB; Bersvendsen HS; Holte H
Acta Oncol; 2020 Jan; 59(1):101-105. PubMed ID: 31429371
[No Abstract] [Full Text] [Related]
26. Facial swelling: an atypical presentation of cutaneous lymphoma.
Lee WJ; Moon IJ; Won CH; Chang SE; Choi JH; Moon KC; Lee MW
Int J Dermatol; 2016 Aug; 55(8):e440-6. PubMed ID: 26945567
[TBL] [Abstract][Full Text] [Related]
27. Brentuximab vedotin in the treatment of CD30+ PTCL.
Barta SK; Gong JZ; Porcu P
Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study.
Chang ALS; Tran DC; Cannon JGD; Li S; Jeng M; Patel R; Van der Bokke L; Pague A; Brotherton R; Rieger KE; Satpathy AT; Yost KE; Reddy S; Sarin K; Colevas AD
J Am Acad Dermatol; 2019 Feb; 80(2):564-566. PubMed ID: 30145186
[No Abstract] [Full Text] [Related]
29. Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience.
Nanni L; Pellegrini C; Stefoni V; Argnani L; Cavo M; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e595-e596. PubMed ID: 31543370
[No Abstract] [Full Text] [Related]
30. Precursor B- or T-lymphoblastic lymphoma presenting with cutaneous involvement: a series of 13 cases including 7 cases of cutaneous T-lymphoblastic lymphoma.
Lee WJ; Moon HR; Won CH; Chang SE; Choi JH; Moon KC; Lee MW
J Am Acad Dermatol; 2014 Feb; 70(2):318-25. PubMed ID: 24314877
[TBL] [Abstract][Full Text] [Related]
31. Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.
Hofer V; Maurus K; Houben R; Schrama D; Roth S; Goebeler M; Geissinger E; Rosenwald A; Wobser M
J Cutan Pathol; 2022 Mar; 49(3):314-317. PubMed ID: 34854114
[No Abstract] [Full Text] [Related]
32. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
Br J Haematol; 2020 May; 189(3):e86-e90. PubMed ID: 32048731
[No Abstract] [Full Text] [Related]
33. New biotherapies for the treatment of cutaneous T-cell lymphomas.
de Masson A
Presse Med; 2022 Mar; 51(1):104110. PubMed ID: 35026391
[TBL] [Abstract][Full Text] [Related]
34. Brentuximab vedotin monotherapy is an effective treatment in a frail pediatric patient with Down syndrome and classical Hodgkin lymphoma.
Vonasek J; Edslev PW; d'Amore F; Hasle H
Pediatr Blood Cancer; 2020 Feb; 67(2):e28082. PubMed ID: 31724794
[No Abstract] [Full Text] [Related]
35. Intralesional brentuximab vedotin for the treatment of primary cutaneous T-cell lymphomas: a case series.
Arroyo-Andrés J; Agud-Dios M; Rubio-Muniz CA; Postigo C; Cortijo-Cascajares S; Ortiz-Romero PL
Int J Dermatol; 2024 Feb; 63(2):e57-e59. PubMed ID: 38093412
[No Abstract] [Full Text] [Related]
36. Brentuximab vedotin as consolidation after hematopoietic cell transplant for relapsed Hodgkin lymphoma in pediatric patients.
Flerlage JE; von Buttlar X; Krasin M; Triplett B; Kaste SC; Metzger ML
Pediatr Blood Cancer; 2019 Dec; 66(12):e27962. PubMed ID: 31429511
[No Abstract] [Full Text] [Related]
37. [Cardiac infiltration as complication of cutaneous T-lymphoblastic non-Hodgkin's lymphoma].
Opherk JP; Lotz J; Galanski M
Rofo; 2007 Feb; 179(2):175-6. PubMed ID: 17199184
[No Abstract] [Full Text] [Related]
38. Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression.
Saintes C; Saint-Jean M; Renaut JJ; Dréno B; Quéreux G
Br J Dermatol; 2015 Mar; 172(3):819-21. PubMed ID: 25113163
[No Abstract] [Full Text] [Related]
39. Brentuximab induced CD30
Nikolaou V; Iliakis T; Marinos L; Economidi A; Panayiotidis P; Rigopoulos D; Stratigos AJ
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e147-e148. PubMed ID: 30520137
[No Abstract] [Full Text] [Related]
40. Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study.
Suri A; Mould DR; Liu Y; Jang G; Venkatakrishnan K
Clin Pharmacol Ther; 2018 Nov; 104(5):989-999. PubMed ID: 29377077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
